Moderna Gets $50 Million to Develop mRNA Ebola Vaccine Against Bundibugyo
CEPI said the candidates could reach clinical trials in a few months as the outbreak tops 1,100 suspected cases, officials said.
- On Monday, Moderna and the Coalition for Epidemic Preparedness Innovations announced an expanded partnership to accelerate development of an investigational vaccine against Ebola Bundibugyo.
- The outbreak has caused 282 confirmed cases, including 42 deaths, and around 1,100 suspected cases in eastern Democratic Republic of Congo, with the Africa Centres for Disease Control and Prevention and World Health Organization declaring it a public health emergency.
- CEPI committed up to $50 million to support preclinical development and early clinical testing of Moderna's candidate, which uses the same mRNA platform that enabled rapid vaccine production during the COVID-19 pandemic.
- Separately, global vaccine alliance Gavi committed up to $50 million to the response, while the World Bank's Pandemic Fund announced up to $220.6 million in grants to support outbreak control efforts.
- CEPI CEO Richard Hatchett emphasized urgency, stating, "Every day counts in the race against this deadly disease," while cautioning that unpredictable development cycles and regional security concerns complicate trials.
54 Articles
54 Articles
Together with CEPI, the US biotech company is developing a vaccine against the Bundibugyo variant of the Ebola virus. The partners are thus responding to the ongoing Ebola outbreak in the east of the Congo.
International efforts accelerate development of vaccine against Ebola's Bundibugyo strain
Geneva: International organisations on Monday announced intensified efforts to respond urgently to the Ebola outbreak in the Democratic Republic of the Congo and Uganda, while accelerating the development of an effective vaccine against the circulating Bundibugyo strain.The outbreak, which has so far caused around 250 deaths and more than 1,100 confirmed cases, has prompted scientists and international health organisations to race against time t…
Moderna, the Serum Institute of India with the University of Oxford, and the global coalition for the AIDS vaccine Iavi receive funding; Moderna receives US$50 million.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
